Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Kelun-Biotech Could Raise $208 Million in Hong Kong IPO for ADC Portfolio

publication date: Jun 30, 2023

Sichuan Kelun-Biotech could reap up to $208.5 million in its upcoming Hong Kong IPO, if it prices at the top of the range, which drops to $175.5 million if its prices in the middle. Founded in 2016, Kelun is a prominent developer of ADC drugs that is best known for signing three deals in 2022 to out-license 10 ADC candidates to Merck for deals that brought in $257 million upfront – more than the IPO – and could be worth up to $12.7 billion if everything goes perfectly. Kelun considers itself a leader in ADC candidates, though it also develops other biologics and small molecules drugs. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China